Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: jelrod3 who wrote (2881)	5/25/1998 11:25:00 PM
From: ctirry	Read Replies (1) \| Respond to of 9523

Now let's be fair and quote the rest of the article... But while a greater reduction in LDL cholesterol--as seen with atorvastatin--means a lower risk for cardiovascular events, researchers have not yet proven that atorvastatin, in particular, reduces myocardial infarction and stroke, Dr. Gordon noted. Simvastatin, pravastatin and lovastatin, on the other hand, have been demonstrated in previous studies to lower these cardiovascular complications, he said. "I don't know if you can jump from this paper and say everyone should throw out their simvastatin or pravastatin and start taking atorvastatin," Dr. Gordon said.